Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
Dispatch

Early Detection of Pandemic (H1N1) 2009, Bangladesh

Eduardo Azziz-BaumgartnerComments to Author , Mustafizur Rahman, Abdullah Al Mamun, Mohammad Sabbir Haider, Rashid Uz Zaman, Polash Chandra Karmakar, Sharifa Nasreen, Syeda Mah-E Muneer, Nusrat Homaira, Doli Rani Goswami, Be-Nazir Ahmed, Mohammad Mushtuq Husain, Khondokar Mahbuba Jamil, Selina Khatun, Mujaddeed Ahmed, Apurba Chakraborty, Alicia Fry, Marc-Alain Widdowson, Joseph S. Bresee, Tasnim Azim, A.S.M. Alamgir, Abdullah Brooks, Mohamed Jahangir Hossain, Alexander Klimov, Mahmudur Rahman, and Stephen P. Luby
Author affiliations: International Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh (E. Azziz-Baumgartner, M. Rahman, A.A. Mamun, R.U. Zaman, P.C. Karmakar, S. Nasreen, S. Mah-E-Muneer, N. Homaira, D.R. Goswami, A. Chakraborty, T. Azim, A. Brooks, M.J. Hossain, S.P. Luby); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Azziz-Baumgartner, A. Fry, M.-A. Widdowson, J. Bresee, A. Klimov, S.P. Luby); Institute of Epidemiology, Disease Control and Research, Dhaka (M.S. Haider, B.-N. Ahmed, M.M. Husain, K.M. Jamil, A. Chakraborty, A.S.M. Alamgir, M. Rahman); World Health Organization, Dhaka (S. Khatun, M. Ahmed)

Main Article

Table 2

Clinical description of case-patients infected with pandemic (H1N1) 2009 virus seeking treatment, by surveillance platform, Bangladesh, June 2009–October 2010

Description of case-patient Event-based surveillance,
n = 182 (%) Sentinel-site surveillance,
n = 527 (%) Kamalapur community-based surveillance,
n = 621 (%) Mirpur community-based surveillance,
n = 41 (%)
At high risk for complications from influenza illness 79 (43) 331 (63) 285 (4) 41 (100)
Preexisting conditions* 54 (30)† 182 (35) 22 (3) 0
Danger signs (i.e., difficulty breathing or shortness of breath) 50 (27 )† 230 (44) 47 (8) 5 (12)
Treated with oseltamivir‡ when treatment indicated† 4/56 (84) 7/207 (3) 81/272 (30) 1/41 (2)
Median days from symptom onset to treatment with oseltamivir 2 (2–4) 5 (2–8) 4 (1–5) 5
Hospitalization 29 (16)† 259 (49) 0 0
Death 3 (2)† 25 (5) 0 0

*Preexisting conditions among event and sentinel site surveillance case-patients included asthma (71[10%]), chronic obstructive lung disease (31 [4%]), obesity (47 [7%]), immune suppression (20 [3%]), diabetes (12 [2%]), chronic heart disease (10 [1%]), neuromuscular disorders (10 [1%]), liver disease (10 [1%]), and hematologic disorders (8 [1%]), cancer (3 [0.4%]), and pregnancy (3 [0.4%]), while 2 community-based surveillance case-patients had immunosuppression (0.3%), 2 (0.3%) had asthma, and 1 (0.1%) had diabetes.
†Comparison between surveillance sites, Pearson χ2 p<0.0001.
‡Oseltamivir 5 mg 2×/d for 5 days.

Main Article

Page created: December 19, 2011
Page updated: December 19, 2011
Page reviewed: December 19, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external